Picard Medical, Inc. (PMI) Stock

About Picard Medical, Inc.

Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.

Picard Medical, Inc. is led by CEO Patrick N. J. Schnegelsberg, employs 75 people, headquartered in US, publicly traded since 2025.

Picard Medical, Inc. (PMI) stock trades at $0.09 with a market capitalization of $137.11M. The stock is valued at a price-to-earnings (P/E) ratio of -0.20, price-to-book of -4.52, price-to-sales of 25.03. Over the past 52 weeks the stock has ranged between $0.09 and $13.68, and currently trades 99.3% below its 52-week high.

On profitability, Picard Medical, Inc. generates a return on equity (ROE) of 499.20% — well above the market average, a sign of a high-quality business, return on capital employed of 977.41%, an operating margin of -260.00%, a net profit margin of -545.02%.

Official website: www.picardmedical.com